Middle East experience from the Asia And Latin America Fracture Observational Study (ALAFOS): Baseline characteristics of postmenopausal women with osteoporosis using teriparatide

Abstract

Objective We aimed to describe the baseline clinical characteristics and fracture history of patients taking teriparatide in routine clinical practice in the Middle East (ME) subregional cohort of the Asia and Latin America Fracture Observational Study (ALAFOS). Methods Herein, we report baseline clinical characteristics of patients who were prescribed teriparatide (20 µg/day, subcutaneous injection) in four participant ME countries (Saudi Arabia, United Arab Emirates, Kuwait, and Lebanon). Results The ME cohort included 707 patients mean (SD) age 69.3 (11.6) years. Mean (SD) bone mineral density (BMD) T-scores at baseline were −3.13 (1.28) for lumbar spine, −2.88 (0.94) for total hip, and −2.65 (1.02) for femoral neck. Osteoporotic fractures after age 40 years were reported in 45.8% (vertebral fracture 14.4%, hip fracture 18.4%) and comorbidities in 57.4% of patients. Before starting teriparatide, 19.9% of patients took other osteoporosis medications. The median (Q1; Q3) EuroQoL 5-Dimension 5-Level visual analog scale score for perceived overall health status was 70 (50; 80). Mean (SD) worst back pain in the previous 24 hours was 4.0 (3.2) using a 10-point numeric rating scale. Conclusion This analysis indicated that in ME countries, teriparatide is usually prescribed to patients with low BMD and high comorbidities, with prior fractures.

The Effect of Teriparatide Treatment on the Risk of Fragility Fractures in Postmenopausal Women with Osteoporosis: Results from the Asian and Latin America Fracture Observational Study (ALAFOS)

“…Due to these differences, as well as differences in local clinical care, the baseline characteristics of the patients at risk for fractures and included in this study differed from those previously reported in other observational studies with teriparatide, particularly from those conducted in Europe: ExFOS and EFOS. The largest differences in the cohorts were prevalent fracture status and prior osteoporosis treatment [ 19 , 20 , 25 , 31 , 32 ]. In the current study, 36.8% of patients had not suffered an osteoporotic fracture before baseline.…”

Application of the EQ-5D in the Middle East: A Systematic Review Focusing on Patients Living in the Kingdom of Saudi Arabia

“…The most studied condition was diabetes mellitus (n=4), 23–26 followed by musculoskeletal disorders, back pain, and injuries (n=3). 27–29 The remaining articles focused either on a specific condition, such as urinary tract infections, 30 chronic obstructive pulmonary disease, 31 or multiple sclerosis; 32 on a treatment, such as teriparatide, 33 warfarin, or apixaban; 34 or on a nonspecific condition. 35 For all the reviewed studies, only one study reported the Cronbach’s alpha value of 0.72, which could indicate an acceptable reliability and an opportunity for enhancement.…”

“…Journal of Multidisciplinary Healthcare 2021:14 1102 tract infections, 30 chronic obstructive pulmonary disease, 31 or multiple sclerosis; 32 on a treatment, such as teriparatide, 33 warfarin, or apixaban; 34 or on a nonspecific condition. 35 For all the reviewed studies, only one study reported the Cronbach's alpha value of 0.72, which could indicate an acceptable reliability and an opportunity for enhancement.…”

Functional Results of Cephalomedullary Nail Osteosynthesis of Transtrochanteric Fractures in Elderly Patients

“…За оцінками Міжнародного фонду остеопорозу (The International Osteoporosis Foundation), у світі очікується зростання кількості переломів стегнової кістки внаслідок низькоенергетичного механізму травми з 1,7 млн (станом на 1990 рік) до 6,3 млну 2050 році [5]. А внаслідок поширення остеопорозу на фоні подовження тривалості життя прогнозовані показники частоти переломів ПВСК до 2050 року можуть перевищити 8,2 млн [6].…”